Track Every Presidential Action. Understand the Impact.

Regulatory Relief to Promote Domestic Production of Critical Medicines

President Donald Trump issued an order to streamline regulations for domestic pharmaceutical manufacturing to enhance national security and reduce dependency on foreign sources. The order directs the Secretary of Health and Human Services and the FDA Commissioner to review and eliminate unnecessary regulations that hinder the development of pharmaceutical manufacturing in the United States. It also calls for improvements in the inspection processes for both domestic and foreign manufacturing facilities. Additionally, the Environmental Protection Agency and the U.S. Army Corps of Engineers are tasked with updating their regulations to facilitate faster approval and expansion of manufacturing facilities. This action aims to make the U.S. a more competitive environment for the production of essential medicines.